Cadence Pharmaceuticals Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
210
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.33B
Cadence Pharmaceuticals General Information
Description
Developer of proprietary product candidates principally for use in hospital settings. The company has rights to one product candidate, Ofirmev, a proprietary intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children.
Contact Information
Corporate Office
- 12481 High Bluff Drive
- Suite 200
- San Diego, CA 92130
- United States
Corporate Office
- 12481 High Bluff Drive
- Suite 200
- San Diego, CA 92130
- United States
Cadence Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 19-Mar-2014 | $1.33B | Completed | Generating Revenue | ||
| 6. Debt - General | 21-Jun-2010 | Completed | Generating Revenue | |||
| 5. PIPE | 19-Feb-2009 | Completed | Generating Revenue | |||
| 4. IPO | 25-Oct-2006 | Completed | Clinical Trials - Phase 3 | |||
| 3. Early Stage VC (Series A3) | 22-Feb-2006 | Completed | Product Development | |||
| 2. Early Stage VC (Series A2) | 11-Oct-2005 | $17.7M | $25.3M | Completed | Product Development | |
| 1. Early Stage VC (Series A1) | 01-Aug-2004 | $7.6M | $7.6M | Completed | Product Development |
Cadence Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | 8,085,108 | 8% | $0.94 | $0.94 | $0.94 | 9.89% |
Cadence Pharmaceuticals Comparisons
Industry
Financing
Details
Cadence Pharmaceuticals Competitors (3)
One of Cadence Pharmaceuticals’s 3 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| OncBioMune Pharmaceuticals | Corporate Backed or Acquired | Baton Rouge, LA | ||||
| Knoa Pharma | Corporate Backed or Acquired | Stamford, CT |
Cadence Pharmaceuticals Signals
Cadence Pharmaceuticals Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BB Biotech Ventures | Venture Capital | Minority | ||
| Bay City Capital | Venture Capital | Minority | ||
| CDIB BioScience Venture Management | Venture Capital | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority |
Cadence Pharmaceuticals Investments (1)
Cadence Pharmaceuticals’s most recent deal was a Early Stage VC with Incline Therapeutics for . The deal was made on 13-Sep-2011.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Incline Therapeutics | 13-Sep-2011 | Early Stage VC | Drug Discovery |
Cadence Pharmaceuticals FAQs
-
When was Cadence Pharmaceuticals founded?
Cadence Pharmaceuticals was founded in 2004.
-
Where is Cadence Pharmaceuticals headquartered?
Cadence Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of Cadence Pharmaceuticals?
Cadence Pharmaceuticals has 210 total employees.
-
What industry is Cadence Pharmaceuticals in?
Cadence Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Cadence Pharmaceuticals a private or public company?
Cadence Pharmaceuticals is a Private company.
-
What is the current valuation of Cadence Pharmaceuticals?
The current valuation of Cadence Pharmaceuticals is .
-
What is Cadence Pharmaceuticals’s current revenue?
The current revenue for Cadence Pharmaceuticals is .
-
How much funding has Cadence Pharmaceuticals raised over time?
Cadence Pharmaceuticals has raised $223M.
-
Who are Cadence Pharmaceuticals’s investors?
BB Biotech Ventures, Bay City Capital, CDIB BioScience Venture Management, Domain Associates, and Frazier Healthcare Partners are 5 of 13 investors who have invested in Cadence Pharmaceuticals.
-
Who are Cadence Pharmaceuticals’s competitors?
Astellas Pharma, OncBioMune Pharmaceuticals, and Knoa Pharma are competitors of Cadence Pharmaceuticals.
-
When was Cadence Pharmaceuticals acquired?
Cadence Pharmaceuticals was acquired on 19-Mar-2014.
-
Who acquired Cadence Pharmaceuticals?
Cadence Pharmaceuticals was acquired by Mallinckrodt Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process